We have heard quite a bit about substance abuse with the help of many substances including various naturally occurring Canabinoids. However, recent research has shown that when it comes to management of chronic pain and also pains associated with various types of cancers, canabinoids could be the way forward. This has been understood by a few companies and Gala Pharmaceutical Inc., is one such firm. It is Gala Pharmaceutical Inc., California, which is on the threshold of literally setting new benchmarks as far as research and studies in Cannabis and other such substances are concerned. Hence, as an investor if you are looking for a low cost but potentially high return stock investment, then GLPH could be the right choice. By the way GLPH is the acronym for Gala Pharmaceutical Inc.
Any organization, big or small, is as good or bad as the products and services it offers. The same applies to GLPH. Over the past year or so, this firm having its Head Office in Irvine, California is catching the attention of experts in the field of cannabis. It is fast emerging to be a testing center for cannabis. It is expected that in the next couple of year, this company would have developed a highly efficient, reliable and technologically advanced network of cannabis testing laboratories across the state. This is being planned with the objective of making cannabis reach out to more number of end users as a pain management medication.
It is also strongly believed that a new and more progressive law pertaining to Cannabis should be in place in California by the end of the year 2018. Hence, this will be in line with the ambitious plans which GLPH has when it comes to setting up testing centers and laboratories across the place. The company feels that it has some unique advantages when compared to competition. These include location advantages and more importantly a highly qualified, experienced and professional team.
Any organization is able to scale new heights of success because it may have been endowed with the best of talents. The same is the case with Gala Pharmaceutical Inc. It has two amazing personalities who are the movers and shakers. They are the Chief Executive Officer and the Chief Scientific Officer. Both of them are highly qualified and are PhD holders and Doctorate Degree holders in their respective areas. They thoroughly understand cannabis as a possible game changer in the future when it comes to managing chronic pain.
As GLPH is on the threshold of a big expansion, aided and abetted by government concessions and other such factors, it would be foolish not to invest in the scripts of this company. They will be tapping into a $25 billion market in California alone and therefore the share prices of this company will in all probabilities become out of reach over the next two or three years. If you are smart, patient and believe in the future of cannabis related drugs, then you must spare some decent money as a small investor. You have many reasons to repose your faith on GLPH and it will not be long before you see the desired results.